ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. It is characterized by the gradual loss of muscle control, which can lead to paralysis and death.

The cause of ALS is unknown, but it is thought to be caused by a combination of genetic and environmental factors. There is no cure for ALS, but there are treatments that can help to slow the progression of the disease and improve quality of life.

Articles on this page look at the latest research in new ALS cell therapies and drugs, and there are also personal profiles of people living with and fighting amyotrophic lateral sclerosis.

Latest

Health tech Timmy Broderick

All Coverage

Politics John Wilkerson

ALS

Latest

STAT Plus: ALS patient lived with a brain-computer interface for 7 years. Here’s what researchers learned

First Opinion readers respond to psychiatry and social contracts, Medicare and weight loss meds, and more

My stalled relay race to get access to ALS drugs in development

Congress called for an ALS moonshot. The plan for it doesn’t leave Earth

STAT Plus: How Harvard researchers boosted an ALS patient’s independence with a box and a balloon

STAT Plus: Patient advocates clash over wisdom of ‘approving drugs faster and faster’

A dilemma in ALS, the first MASH drug, & why gene therapy is hard

After Amylyx ALS trial failure, patients share disappointment and fear — but some hope

All Coverage

STAT Plus: ALS patients support bill that could help patients with other rare diseases

Live from the 2023 STAT Summit

STAT Plus: What we owe ALS patients — and why one company fell short

STAT Plus: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm

STAT Plus: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds

A thorny ALS debate at the FDA, and the promise of artificial wombs

They carry a gene for ALS but aren’t sick. What does medical research owe them?

STAT Plus: What to know about the polarizing ALS drug headed for FDA scrutiny

STAT Plus: FDA approves new treatment from Biogen for rare form of ALS

STAT Plus: FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding

When spinal fluid from ALS patients was put into mice, the mice got weak. An unlikely protein could be the culprit

Private equity in autism care, a watershed FDA approval, and the future of ALS treatment

STAT Plus: Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections

STAT Plus: FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street

STAT Plus: Biogen drug for rare form of ALS fails pivotal study — another setback for fatal disease with few treatments

STAT Plus: Brainstorm’s cell therapy for ALS fails study, but company sees signs of efficacy — and may push for approval

STAT Plus: Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome

Head trauma link to ALS strengthened with findings of NFL player Kevin Turner’s autopsy

ALS patient takes on one final fight: jump-starting research

For ALS patients robbed of speech, a new way of ‘speaking’